Top upfront cash licensing deals in '17 Bayer/L
Post# of 72440
(Total Views: 775)
Posted On: 04/12/2019 3:14:00 AM
Top upfront cash licensing deals in '17
Bayer/Loxo Ph2 $400M upfront Onc.
Novartis/Ions Ph2 $375M upfront Cardio' V
Nanjing Legend/Janssen Ph2 $350M upfront Onc
Biogen/Bristol Myers Ph1 $300M upfront Neurology
Merck/Vertex Ph2 $230M upfront Onc.
AbbV/Alector Discovery stage $205M upfront Neurology
Roche/Bristol Myers Ph1 $170M upfront Musculoskeletal
EliLilly/Nektar Ph1 $150M upfront Auto Imm/Inflam
Sanofi/Astrazeneca Ph2 $126M upfront Infection
Dermira/Roche Ph2 $80M upfront Dermatologic
Looks to me BP is wiling to pay up earlier
Bayer/Loxo Ph2 $400M upfront Onc.
Novartis/Ions Ph2 $375M upfront Cardio' V
Nanjing Legend/Janssen Ph2 $350M upfront Onc
Biogen/Bristol Myers Ph1 $300M upfront Neurology
Merck/Vertex Ph2 $230M upfront Onc.
AbbV/Alector Discovery stage $205M upfront Neurology
Roche/Bristol Myers Ph1 $170M upfront Musculoskeletal
EliLilly/Nektar Ph1 $150M upfront Auto Imm/Inflam
Sanofi/Astrazeneca Ph2 $126M upfront Infection
Dermira/Roche Ph2 $80M upfront Dermatologic
Looks to me BP is wiling to pay up earlier
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼